BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23665980)

  • 21. Rituximab maintenance therapy of relapsed or refractory follicular lymphoma, with longer follow-up: no proven impact on survival.
    Prescrire Int; 2012 Mar; 21(125):63. PubMed ID: 22428183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
    Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
    J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
    Witzig TE; Vukov AM; Habermann TM; Geyer S; Kurtin PJ; Friedenberg WR; White WL; Chalchal HI; Flynn PJ; Fitch TR; Welker DA
    J Clin Oncol; 2005 Feb; 23(6):1103-8. PubMed ID: 15657404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH).
    Gnekow AK; Kortmann RD; Pietsch T; Emser A
    Klin Padiatr; 2004; 216(6):331-42. PubMed ID: 15565548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab maintenance therapy for follicular lymphoma: no better than watchful waiting.
    Prescrire Int; 2012 Mar; 21(125):62. PubMed ID: 22428182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
    Pettengell R; Schmitz N; Gisselbrecht C; Smith G; Patton WN; Metzner B; Caballero D; Tilly H; Walewski JA; Bence-Bruckler I; To B; Geisler CH; Schots R; Kimby E; Taverna CJ; Kozák T; Dreger P; Uddin R; Ruiz de Elvira C; Goldstone AH
    J Clin Oncol; 2013 May; 31(13):1624-30. PubMed ID: 23547078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
    Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E
    Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment.
    Arcaini L; Colombo N; Passamonti F; Burcheri S; Orlandi E; Brusamolino E; Della Porta M; Rumi E; Montanari F; Pascutto C; Paulli M; Lazzarino M
    Leuk Res; 2006 Mar; 30(3):277-82. PubMed ID: 16112730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.
    Montoto S; Moreno C; Domingo-Doménech E; Estany C; Oriol A; Altés A; Besalduch J; Pedro C; Gardella S; Escoda L; Asensio A; Vivancos P; Galán P; de Sevilla AF; Ribera JM; Briones J; Colomer D; Campo E; Montserrat E; López-Guillermo A;
    Haematologica; 2008 Feb; 93(2):207-14. PubMed ID: 18223288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.
    Martinelli G; Schmitz SF; Utiger U; Cerny T; Hess U; Bassi S; Okkinga E; Stupp R; Stahel R; Heizmann M; Vorobiof D; Lohri A; Dietrich PY; Zucca E; Ghielmini M
    J Clin Oncol; 2010 Oct; 28(29):4480-4. PubMed ID: 20697092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphoma in children and adolescents. Part 3: An intermediate term analysis of the B-NHL/B-ALL].
    Reiter A; Schrappe M; Yakisan E; Sauter S; Ebell W; Zimmermann M; Hartmann W; Kremens B; Kuhn N; Claviez A
    Klin Padiatr; 1994; 206(4):242-52. PubMed ID: 7967420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma.
    Mauz-Körholz C; Gorde-Grosjean S; Hasenclever D; Shankar A; Dörffel W; Wallace WH; Schellong G; Robert A; Körholz D; Oberlin O; Hall GW; Landman-Parker J
    Cancer; 2007 Jul; 110(1):179-85. PubMed ID: 17526010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.
    Sacchi S; Pozzi S; Marcheselli L; Bari A; Luminari S; Angrilli F; Merli F; Vallisa D; Baldini L; Brugiatelli M;
    Cancer; 2007 May; 109(10):2077-82. PubMed ID: 17394190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characteristics and treatment results of pediatric B-cell non-Hodgkin lymphoma patients in a single center.
    Karadeniz C; Oguz A; Citak EC; Uluoglu O; Okur V; Demirci S; Okur A; Aksakal N
    Pediatr Hematol Oncol; 2007 Sep; 24(6):417-30. PubMed ID: 17710659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Large cell non-Hodgkin lymphoma of childhood: clinical characteristics and outcome.
    Sandlund JT; Santana V; Abromowitch M; Ribeiro R; Mahmoud H; Ayers GD; Lin JS; Hutchison RE; Berard CW; Greenwald CA
    Leukemia; 1994 Jan; 8(1):30-4. PubMed ID: 8289495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
    Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
    Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy.
    Guadagnolo BA; Li S; Neuberg D; Ng A; Hua L; Silver B; Stevenson MA; Mauch P
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):928-34. PubMed ID: 16243446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
    Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab for follicular lymphoma: watch and wait, watch and worry, or watch and live?
    LeBlanc T; Kamal A; Abernethy A
    Lancet Oncol; 2014 Jun; 15(7):e251-2. PubMed ID: 24872108
    [No Abstract]   [Full Text] [Related]  

  • 40. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
    Fowler N; Kahl BS; Lee P; Matous JV; Cashen AF; Jacobs SA; Letzer J; Amin B; Williams ME; Smith S; Saleh A; Rosen P; Shi H; Parasuraman S; Cheson BD
    J Clin Oncol; 2011 Sep; 29(25):3389-95. PubMed ID: 21810687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.